1	Opioid use does not limit potent low-dose HIV-1 latency reversal agent boosting
2	
3	Tyler Lilie <sup>1</sup> <sup>†</sup> , Jennifer Bouzy <sup>1</sup> <sup>†</sup> , Archana Asundi <sup>2</sup> , Jessica Taylor <sup>2,3</sup> , Samantha Roche <sup>2</sup> , Alex
4	Olson <sup>2</sup> , Kendyll Coxen <sup>1</sup> , Heather Corry <sup>1</sup> , Hannah Jordan <sup>1</sup> , Kiera Clayton <sup>4</sup> , Nina Lin <sup>2</sup> ‡, Athe
5	Tsibris <sup>1,5</sup> <sup>‡*</sup>
6	† These authors contributed equally to this work
7	‡ These authors contributed equally to this work
8	
9	Affiliations:
10	<sup>1</sup> Brigham and Women's Hospital, Boston, MA, USA.
11	<sup>2</sup> Department of Medicine, Boston University School of Medicine & Boston Medical
12	Center, Boston, MA USA.
13	<sup>3</sup> Grayken Center for Addiction, Boston Medical Center, Boston, MA USA.
14	<sup>4</sup> Department of Pathology, University of Massachusetts T.H. Chan School of Medicine,
15	Worcester, MA, USA.
16	<sup>5</sup> Harvard Medical School, Boston, MA, USA.
17	*Corresponding author: <u>atsibris@bwh.harvard.edu</u>
18	
19	
20	
21	

#### 22 Abstract

23	The combined effects of the HIV-1 and opioid epidemics on virus reservoir dynamics are less
24	well characterized. To assess the impact of opioid use on HIV-1 latency reversal, we studied
25	forty-seven suppressed participants with HIV-1 and observed that lower concentrations of
26	combination latency reversal agents (LRA) led to synergistic virus reactivation ex vivo,
27	regardless of opioid use. The use of a Smac mimetic or low-dose protein kinase C agonist,
28	compounds that did not reverse latency alone, in combination with low-dose histone deacetylase
29	inhibitors generated significantly more HIV-1 transcription than phorbol 12-myristate 13-acetate
30	(PMA) with ionomycin, the maximal known HIV-1 reactivator. This LRA boosting did not differ
31	by sex or race and associated with greater histone acetylation in CD4 <sup>+</sup> T cells and modulation of
32	T cell phenotype. Virion production and the frequency of multiply spliced HIV-1 transcripts did
33	not increase, suggesting a post-transcriptional block still limits potent HIV-1 LRA boosting.
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	

#### 45 Introduction

46	HIV-1 proviral DNA remains integrated in CD4 <sup>+</sup> T cells during suppressive antiretroviral
47	therapy (ART) and is a barrier to cure. This virus reservoir is seeded within days of infection
48	before symptoms develop <sup>1,2</sup> , persists <sup>3-5</sup> , decays slowly <sup>6</sup> , and can be maintained indefinitely <sup>7,8</sup> .
49	The best approach to pursue HIV eradication remains uncertain. One strategy aims to
50	pharmacologically reactivate latent HIV transcription in the setting of suppressive ART, induce
51	virus protein production in infected cells, and then clear the reservoir, defined as cells that
52	contain provirus capable of generating infectious virions, through immune-mediated
53	mechanisms <sup>9-11</sup> . HIV-1 latency reversal agents (LRA) have advanced into clinical trials as
54	monotherapy but with modest results; transient increases in virus mRNA production may be
55	observed with some LRA but does not result in a decrease in reservoir size <sup>12-22</sup> . HIV-1 latency
56	may be characterized by transcriptional blocks that cannot be overcome by single LRA <sup>23-26</sup> .
57	To address these limitations, novel classes and combinations of LRA have been studied <sup>27</sup> .
57 58	To address these limitations, novel classes and combinations of LRA have been studied <sup>27</sup> . Epigenetic LRA such as histone deacetylase inhibitors, when combined with protein kinase C
58	Epigenetic LRA such as histone deacetylase inhibitors, when combined with protein kinase C
58 59	Epigenetic LRA such as histone deacetylase inhibitors, when combined with protein kinase C agonists or second mitochondria-derived activator of caspase (Smac) mimetics, have been
58 59 60	Epigenetic LRA such as histone deacetylase inhibitors, when combined with protein kinase C agonists or second mitochondria-derived activator of caspase (Smac) mimetics, have been reported under some conditions to synergistically increase HIV-1 transcription in CD4 <sup>+</sup> T cells
58 59 60 61	Epigenetic LRA such as histone deacetylase inhibitors, when combined with protein kinase C agonists or second mitochondria-derived activator of caspase (Smac) mimetics, have been reported under some conditions to synergistically increase HIV-1 transcription in CD4 <sup>+</sup> T cells isolated from treated suppressed participants with HIV, although the precise mechanism for this
<ul><li>58</li><li>59</li><li>60</li><li>61</li><li>62</li></ul>	Epigenetic LRA such as histone deacetylase inhibitors, when combined with protein kinase C agonists or second mitochondria-derived activator of caspase (Smac) mimetics, have been reported under some conditions to synergistically increase HIV-1 transcription in CD4 <sup>+</sup> T cells isolated from treated suppressed participants with HIV, although the precise mechanism for this synergy is unknown <sup>28-32</sup> . The absolute amount of HIV-1 latency reversal, defined most
<ul> <li>58</li> <li>59</li> <li>60</li> <li>61</li> <li>62</li> <li>63</li> </ul>	Epigenetic LRA such as histone deacetylase inhibitors, when combined with protein kinase C agonists or second mitochondria-derived activator of caspase (Smac) mimetics, have been reported under some conditions to synergistically increase HIV-1 transcription in CD4 <sup>+</sup> T cells isolated from treated suppressed participants with HIV, although the precise mechanism for this synergy is unknown <sup>28-32</sup> . The absolute amount of HIV-1 latency reversal, defined most commonly as induced levels of HIV-1 cell-associated RNA (caRNA), reported with combination
<ul> <li>58</li> <li>59</li> <li>60</li> <li>61</li> <li>62</li> <li>63</li> <li>64</li> </ul>	Epigenetic LRA such as histone deacetylase inhibitors, when combined with protein kinase C agonists or second mitochondria-derived activator of caspase (Smac) mimetics, have been reported under some conditions to synergistically increase HIV-1 transcription in CD4 <sup>+</sup> T cells isolated from treated suppressed participants with HIV, although the precise mechanism for this synergy is unknown <sup>28-32</sup> . The absolute amount of HIV-1 latency reversal, defined most commonly as induced levels of HIV-1 cell-associated RNA (caRNA), reported with combination LRA is significantly less than that observed with the maximal HIV-1 reactivator, phorbol 12-

68	People with HIV may be exposed to opioids, whether prescribed for chronic pain <sup>34</sup> ,
69	prescribed for opioid use disorder <sup>35</sup> , or injected as heroin <sup>36</sup> and have nearly double the risk of
70	overdose compared to uninfected people who use opioids <sup>37</sup> . The pharmacology of opioids
71	associated with substance use disorders may differ from opioid medications used to treat chronic
72	pain. The $\mu$ opioid agonists, e.g. heroin, fentanyl, and methadone, can block IL-2 mRNA and
73	protein production in activated T cells through inhibition of AP-1, NFAT, and NF-KB activation,
74	transcription factors known to be positive regulators of HIV transcription initiation <sup>38-40</sup> . The
75	effects of buprenorphine, a partial $\mu$ opioid agonist and $\kappa$ and $\delta$ opioid antagonist used in the
76	treatment of opioid use disorder, on HIV-1 latency and its reversal have not been explored. A
77	recent finding suggested that people with HIV who use opioids may have diminished responses
78	to latency reversal <sup>41</sup> ; LRA efficacy in this burgeoning patient population is understudied.
79	To investigate the mechanisms that control HIV-1 latency reversal during opioid use, we
80	enrolled a cohort of thirty-six treated, virologically suppressed participants with HIV. We tested
81	LRA combinations at concentrations lower than those typically assessed and identified the
82	phenomenon of LRA boosting: synergistic HIV-1 transcriptional reactivation with small
83	molecules that do not reverse latency as single agents. We corroborated these findings in an
84	additional eleven participants from a separate cohort without opioid use and identified key
85	associations between potent LRA boosting, increases in histone acetylation, modulation of T cell
86	phenotype and function, and downstream blocks in HIV-1 virion production. Importantly, we
87	find that opioid use did not limit the magnitude or mechanisms of LRA boosting.

88

89

90

#### 91 **Results**

#### 92 **Opioid use does not affect HIV-1 reservoir size**

93 We enrolled a cohort from a single academic center of thirty-six treated suppressed participants 94 with HIV who used, or did not use, opioids in a 2:1 ratio. Participants had a median age of 59 95 years, included one-third women, and were approximately 30% white (Table 1). The average duration of antiretroviral therapy was 12 years with a median duration of undetectable plasma 96 97 HIV-1 RNA levels of over six years. Participant characteristics were further defined by type of opioid use (Suppl. Table 1) and validated by urine toxicology and self-reported substance use 98 99 questionnaires (Suppl. Fig. 1). This cohort comprised participants who actively injected opioids (n=4), used methadone (n=4) or suboxone (n=12) as medication for opioid use disorder, or took 100 101 opioids for chronic pain (n=4). Amphetamine and barbiturate use was not detected. All active 102 injection opioid users had confirmatory urine toxicology screens positive for fentanyl (n=2 of 4, range 62 - >500 ng/mL) and/or norfentanyl (n=4 of 4 participants, range 46 - >500 ng/mL) and 103 reported a median of 6 days of injection opioid use in the preceding 30 days (IQR 4-16 days) 104 105 with a median of 7 days since the most recent use (IQR 4-14 days). All participants in the 106 methadone, buprenorphine, and prescription opioid subgroups had urine toxicology positive for that substance. 107

To assess markers of HIV-1 persistence, we quantified total HIV-1 DNA and caRNA in PBMC and evaluated intact proviral reservoir size. Total HIV-1 DNA levels were similar between opioid and non-opioid groups, 2.36 vs 2.38 log<sub>10</sub> copies/10<sup>6</sup> PBMC, respectively, as were HIV-1 caRNA levels, 2.45 vs 2.52 log<sub>10</sub> copies/10<sup>6</sup> PBMC (**Fig. 1a**). Levels of intact provirus DNA were also similar between groups, 2.00 vs 1.82 log<sub>10</sub> copies/10<sup>6</sup> PBMC. To better define the intact proviral DNA reservoir, we characterized 5' and 3' HIV-1 deletions across

114	cohorts and opioid use subgroups (Fig. 1b-c). Similar proportions of intact 5' and 3' genetic
115	regions were observed, irrespective of opioid use. The ratios of proviruses containing an intact 5
116	region and a defective (hypermutated) or deleted 3' region in HIV-1 env were statistically
117	similar. An exploratory analysis demonstrated a greater proportion of total genomes were intact
118	in active opioid users (Fig. 1d).

119

#### 120 LRA boosting markedly increases HIV-1 transcription

To determine the effects of opioid use on HIV-1 latency reversal ex vivo, we isolated 121 122 PBMC from all OPHION participants and tested a panel of ten LRA conditions (Fig. 2). The histone deacetylase inhibitors (HDACi) romidepsin (RMD) and panobinostat (PNB) were used at 123 the lowest concentrations most commonly reported in the literature and the protein kinase C 124 agonist bryostatin was tested at 1nM, one-tenth the most commonly reported concentration. In 125 single LRA conditions, we observed a 2.7-fold activation of HIV-1 caRNA transcription, relative 126 to an untreated DMSO-containing control, with  $\alpha$ CD3/ $\alpha$ CD28 beads (95% CI [2.2, 3.2]), a T cell 127 receptor (TCR) agonist (Fig. 2a). Greater reactivation was observed with RMD (3.8-fold 128 increase, 95% CI [3.2, 4.3]) when compared to PNB (2.6-fold increase, 95% CI [2.2, 3.0]). Low-129 dose bryostatin minimally increased unspliced HIV-1 caRNA levels (1.2-fold increase, 95% CI 130 [1.1, 1.4]), but the Smac mimetic AZD5582, at a standard concentration<sup>42</sup>, did not (0.9-fold 131 increase, 95% CI [0.8, 1.1]). 132 We next assessed LRA in combination. Incubation of PBMC with HDACi and either 133 AZD5582 (AZD) or low-dose bryostatin potentiated HIV-1 latency reversal. AZD in 134

135 combination with PNB or RMD increased HIV-1 caRNA levels 8.1-fold (95% CI [6.5, 9.2]) and

136 9.1-fold (95% CI [7.4, 10.8]), respectively. Low-dose bryostatin with PNB increased HIV-1

137	caRNA 10.6-fold (95% CI [8.9, 12.2]), whereas the greatest fold-induction of HIV-1 caRNA was
138	observed with the combination of low-dose bryostatin and RMD (13.2-fold, 95% CI [11.2,
139	15.2]). Statistically greater HIV-1 RNA induction was observed with the LRA boosting
140	combinations relative to HDACi monotherapy and TCR agonism, when corrected for multiple
141	comparisons. We compared LRA response as a function of opioid use (Fig. 2b), sex (Fig. 2c),
142	race (Fig. 2d), and ethnicity (Suppl. Fig. 2) and observed no statistically significant differences
143	in the fold-changes of HIV-1 caRNA induction across these groups. In an exploratory analysis,
144	the fold-change in HIV-1 caRNA varied by opioid use subgroup in response to T cell receptor
145	agonism (Fig. 2e). Statistically significantly greater reactivation was observed in the suboxone
146	sub-group when compared to active injection opioid users, the group with the smallest fold-
147	change in $\alpha$ CD3/ $\alpha$ CD28 bead-induced HIV-1 caRNA levels.

148

#### 149 LRA boosting modulates T cell activation and cytokine production

To understand whether LRA exposure activates CD4<sup>+</sup> T cells, we assessed the 150 151 upregulation of surface activation-induced markers (AIM)<sup>43</sup>. We leveraged dual-marker AIM assays (Suppl. Fig. 3, Fig. 3a), originally developed to detect T cell antigen responsiveness, to 152 quantify cellular activation that occurs with LRA exposure, outside the context of peptide-153 specific recognition. Using TCR agonism as a positive control, responses were detected in 49% 154 (95% CI [45, 54]), 32% (95% CI [28, 35]), and 42% (95% CI [36, 47]) of CD4<sup>+</sup> T cells in the 155 OX40/PDL1, OX40/CD25, and CD69/CD40L AIM assays, respectively (Fig. 3b). Low-dose 156 bryostatin significantly upregulated surface expression to more modest levels in all three AIM 157 assays, relative to an untreated control condition. Bryostatin induced OX40/PDL1 surface 158 159 expression in 5.2% of CD4<sup>+</sup> T cells (95% CI [3,4, 7.0]), levels of induction that did not

significantly change when used in combination with RMD (5.4%, 95% CI [3.3, 7.4]) or PNB 160 (3.5%, 95% CI [2.1, 5.0]). Bryostatin monotherapy induced expression in 6.9% (95% CI [5.6, 161 8.3]) and 2.6% (95% CI [2.0, 3.2]) of CD4s in the OX40/CD25 and CD69/CD40L AIM assays, 162 respectively. In these two assays, the combination of RMD or PNB with low-dose bryostatin 163 164 reduced activation-induced markers, relative to bryostatin alone, in some cases to undetectable levels; these findings did not differ by opioid use. The remainder of the LRA panel and their 165 combinations did not upregulate surface expression in any AIM assay (Suppl. Fig. 4a-c). 166 167 We observed a more pronounced upregulation in isolated CD69 expression, an early 168 activation marker, in response to LRA (Fig. 3c). Approximately 0.5% (95% CI [0.4, 0.7]) of untreated CD4<sup>+</sup> T cells expressed CD69 after 18 hours in culture. The proportion of cells 169 170 expressing surface CD69 significantly increased to similar levels with TCR agonism (68.5%, 171 95% CI [63.1, 73.9]) and low-dose bryostatin (72.9%, 95% CI [69.2, 76.5]). Whereas AZD5582 172 (1.0%, 95% CI [0.7, 1.2]), RMD (4.7%, 95% CI [3.1, 6.3]), and PNB (5.4%, 95% CI [3.8, 7.0]) modestly increased CD69 levels, combinations of these small molecules led to synergistic 173 174 effects. Significantly greater induction of CD69 expression was observed when RMD or PNB 175 was combined with bryostatin or AZD5582; a bryostatin combination induced more CD69 than 176 an HDACi plus AZD5582. CD69 levels were statistically similar when comparing TCR 177 agonism, bryostatin alone, and bryostatin in combination with either HDACi (Suppl. Fig. 4d). 178 To further assess LRA effects on T cell activation, we stained CD4<sup>+</sup> and CD8<sup>+</sup> T cells for intracellular cytokine production (Fig. 3d-e). We observed a cytokine production hierarchy in 179 CD4s, where TNF- $\alpha > IL-2 > IFN-\gamma$ , and in CD8s, where TNF- $\alpha > IFN-\gamma > IL-2$ . In response to 180 181 TCR agonism, significantly more CD4<sup>+</sup> T cells (CD4s) produce TNF-α (30.4%, 95% CI [27.5, 33.4]) than IL-2 (14.3%, 95% CI [12.5, 16.1]) or IFN-γ (6.0%, 95% CI [4.9, 7.1]), and 182

183	significantly more IL-2 than IFN- $\gamma$ (Suppl. Fig. 4e). We identified a different hierarchy in CD8 <sup>+</sup>
184	T cells (CD8s), where the proportion of cells producing TNF- $\alpha$ remained greatest (17.5%, 95%)
185	CI [13.9, 21.1]) but significantly more IFN- $\gamma$ (9.0%, 95% CI [7.1, 10.9]) was produced than IL-2
186	(4.3%, 95% CI [2.8, 5.9]). Whereas HDACi monotherapy did not increase the proportion of
187	CD4s or CD8s producing cytokines compared to an untreated control, low-dose bryostatin alone
188	or in combination with HDACi significantly increased production of TNF- $\alpha$ and, to a smaller
189	magnitude, IFN- $\gamma$ in CD4s. Significantly more CD4s produced TNF- $\alpha$ than IFN- $\gamma$ in response to
190	RMD + bryostatin (4.5%, 95% CI [3.5, 5.6] versus 1.3%, 95% CI [0.9, 1.7]) and PNB +
191	bryostatin (4.2%, 95% CI [3.4, 5.0] versus 1.7%, 95% CI [1.0, 2.4]). In CD8s, low-dose
192	bryostatin significantly increased production of TNF- $\alpha$ (2.8%, 95% CI [1.9, 3.8]) and IFN- $\gamma$
193	(1.5%, 95% CI [0.9, 2.0]). The proportions of CD8s that produced TNF- $\alpha$ and IFN- $\gamma$ when
194	exposed to the combinations of RMD + bryostatin (3.4%, 95% CI [2.5, 4.4] versus 4.7%, 95% CI
195	[2.8, 6.6]) and PNB + bryostatin (4.1%, 95% CI [2.9, 5.3] versus 4.6%, 95% CI [3.0, 6.3]) were
196	similar. IL-2 production did not increase above 0.1% of CD4s or CD8s for any LRA, or
197	combination, we tested. Cytokine production did not differ by opioid use (Suppl. Fig. 5).
198	

199 LRA boosting increases histone acetylation

200 To investigate the mechanism(s) of LRA boosting, we next assessed histone acetylation.

201 The proportions of acetylated histone H3<sup>+</sup> live CD4s were similar between untreated cells

202 (19.7%, 95% CI [16.9, 22.4]) and cells exposed to RMD (21.8%, 95% CI [19.4, 24.3]), PNB

203 (21.7%, 95% CI [19.3, 24.2]), or AZD (19.8%, 95% CI [17.1, 22.6]) and significantly increased

after single-LRA exposure to  $\alpha$ CD3/ $\alpha$ CD28 beads (35.5%, 95% CI [32.7, 38.4]) and low-dose

bryostatin (29.2%, 95% CI [25.7, 32.6]) (Fig. 4a). Low-dose bryostatin in combination with

206	either RMD (36.8%, 95% CI [32.1, 43.2]) or PNB (37.5%, 95% CI [31.8, 43.2]) significantly
207	increased the proportions of CD4s contained acetylated histone H3. Interestingly, statistically
208	significant increases in acetylated histone H3 <sup>+</sup> live CD4s were also observed when combining
209	LRA which individually did not affect acetylation, specifically RMD + AZD ( $30.0\%$ , $95\%$ CI
210	[26.9, 33.1]) and PNB + AZD (29.8%, 95% CI [26.5, 33.0]). These results did not differ by
211	opioid use (Suppl. Fig 6a).
212	Levels of acetylated histone H3, measured by median fluorescence intensity (MFI), were
213	similar in untreated live CD4s and in cells cultured with $\alpha$ CD3/ $\alpha$ CD28 beads, low-dose
214	bryostatin, or AZD (Fig. 4b). Significant 3.4-fold and 3.3-fold increases in acetyl histone MFI
215	were observed for RMD (21482, 95% CI [19014, 23951]) and PNB (21070, 95% CI [18727,
216	23413]), respectively. AZD in combination with RMD or PNB further increased MFI by 6.1-
217	fold and 5.7-fold, respectively. Absolute increases in MFI were observed for low-dose bryostatin
218	in combination with RMD (25498, 95% CI [22772, 28225]) or PNB (27651, 95% CI [24729,
219	30573]) but did not retain significance after correction for multiple comparisons. These results
220	did not differ by opioid use (Suppl. Fig 6b). We observed no association between acetylated
221	histone H3 MFI and fold-change in HIV-1 RNA levels for HDACi monotherapy or for HDACi
222	in combination with AZD (Fig 4c-d). A statistically significant weak association between the
223	proportion of acetyl histone H3 <sup>+</sup> CD4s and fold-change in HIV-1 RNA levels was detected for
224	HDACi in combination with bryostatin (Fig 4e).
225	

226 LRA boosting does not consistently induce virion production

To extend our analyses from the OPHION cohort, we studied an additional eleven
participants with HIV who did not use opioids, enrolled in the HEAL cohort (Suppl. Table 2).

229	We compared LRA boosting responses to the most potent known HIV-1 LRA, PMA in
230	combination with ionomycin (PMA-iono). Significant fold-change increases in HIV-1
231	transcription were observed with combinations of low-dose bryostatin with RMD (8.3-fold, 95%
232	CI [7.2, 9.5]) or PNB (8.0-fold, 95% CI [6.9, 9.0]), when compared to RMD alone (3.4-fold,
233	95% CI [2.6, 4.2]), PNB alone (3.1-fold, 95% CI [2.6, 3.6]), or PMA-iono (1.6-fold, 95% CI
234	[1.4, 1.9]) (Fig. 5a). In separate experiments, we did not observe statistically greater HIV-1
235	transcription with an HDACi in combination with AZD, relative to PMA-iono, in contrast to the
236	results from the larger OPHION cohort (Fig 5b). No significant increases in HIV-1 transcription
237	were observed in PBMC experiments with low-dose bryostatin (1.0-fold, 95% CI $0.9 - 1.1$ ) or
238	AZD (1.2-fold, 95% CI 0.6 – 1.9). Similar magnitudes of HIV-1 transcriptional reactivation were
239	seen with HDACi monotherapy, low-dose bryostatin, and AZD monotherapy across the
240	OPHION and HEAL cohorts we studied. We evaluated human reference gene transcription
241	during LRA treatment and observed decreases with HDACi exposure, increases with PMA-iono,
242	and variable changes with bryostatin (Suppl. Fig. 7). <sup>44,45</sup>
243	To assess the magnitude of HIV-1 latency reversal as a function of cell type, we next
243	
244	performed parallel experiments in PBMC and total CD4 <sup>+</sup> T cells (Fig. 5c). Levels of HIV-1
245	caRNA were, on average, 4.3-fold higher (range $3.2 - 6.0$ ) across experimental conditions
246	performed in CD4 <sup>+</sup> T cells, when compared to PBMC, and varied by 1.6 log <sub>10</sub> (PBMC) and 1.8
247	log <sub>10</sub> (CD4) across participant samples in the absence of LRA. To control for absolute caRNA
248	differences, we determined fold-changes in LRA response and observed statistically significant
249	increases in HIV-1 caRNA with low-dose bryostatin in combination with RMD or PNB, when
250	compared to PMA-iono, in both PBMC and CD4s (Fig. 5d). To explore the variance in LRA
251	response, we compiled per-participant biological replicate measurements (Suppl. Fig. 8a).

252	Supernatant HIV-1 RNA levels increased after 24hr incubation of PBMC with PMA-iono (19
253	copies/mL, 95% CI [10, 32]) and the combinations of RMD plus bryostatin (27 copies/mL, 95%
254	CI [11, 34]) or AZD (31 copies/mL, 95% CI [14, 43]), and PNB plus bryostatin (35 copies/mL,
255	95% CI [19, 60]) or AZD (12 copies/mL, 95% CI [8.1, 26]), when compared to untreated PBMC
256	(3.0 copies/mL, 95% CI [2.2, 6.9]), but these results were not statistically significant after
257	correction for multiple comparisons (Fig. 5e). This virion production response was biphasic. For
258	each LRA condition, PBMC samples from at least 5 of 10 participants showed no increases in
259	HIV-1 RNA levels over control; these were most commonly the same participants. Additionally,
260	no significant increases in LRA-induced virion production in CD4 <sup>+</sup> T cell cultures were
261	observed. Notably, greater virion production in untreated CD4s and greater absolute magnitudes
262	of supernatant viremia in LRA treated CD4s were noted, relative to PBMC, but were again
263	driven by increases from a subset of participants. To investigate the nature of this post-
264	transcriptional block more precisely, we quantified the frequency of CD4s with inducible
265	multiply spliced HIV-1 RNA transcripts (Fig. 5f) <sup>46</sup> . No significant increases in HIV-1 <i>tat/rev</i>
266	transcripts were observed with RMD in combination with bryostatin at either 1nM or 10nM
267	concentrations. In a post-hoc analysis, we combined datasets from OPHION and HEAL
268	participants, including LRA conditions common to both sets of experiments, and observed
269	statistically significant increases in HIV-1 unspliced RNA transcription with all LRA boosting
270	combinations (Fig. 5g). The variance in LRA response increased as the magnitude of fold change
271	in HIV-1 caRNA increased (Suppl. Fig 8b).

272

273

274

#### 275 **Discussion**

Opioid use is complex and can be accompanied by comorbidities, such as immune 276 activation with injection drug use <sup>47,48</sup>, that may impact the HIV-1 reservoir and its persistence 277 <sup>45,49-52</sup>. Here, we found no effects of opioid use by indication, type, or pharmacology on markers 278 of HIV-1 persistence. In the setting of persistently suppressed viremia, opioid use was less likely 279 to modulate virus reservoir size. While our OPHION study participants were older than opioid 280 users experiencing the greatest number of overdose deaths <sup>53</sup>, they do reflect an age more typical 281 282 for patients with HIV who engage in research locally. Overall, participants were matched on the duration of ART and the duration of virus suppression, key variables that have been associated 283 with HIV-1 reservoir size, <sup>54</sup> and our urine toxicology results were consistent with the 284 participants' ascribed opioid use group. We found that opioid use generally did not impact LRA 285 responsiveness, in contrast to a recent smaller study <sup>41</sup>. Our relatively large sample size allowed 286 287 us to determine that this potency was less likely to be affected by sex, race, or ethnicity. We used these samples to identify and characterize the phenomenon of LRA boosting: 288 improving the potency of HDACi beyond that of PMA-ionomycin by combining with a 2<sup>nd</sup> drug 289 that does not, by itself, re-activate HIV-1 transcription. This boosting occurred at lower LRA 290 concentrations, here at least half the RMD and 1/10<sup>th</sup> the bryostatin concentrations used in prior 291 combination studies <sup>28-31</sup>. The specific synergistic latency reversal effects of low-dose bryostatin 292 293 and romidepsin was previously identified in samples from four participants with HIV<sup>28</sup>. Here we confirm those findings in a larger sample size and extend the observation to HDACi more 294 generally. While AZD5582 monotherapy induced virus transcription in tissues from animal 295 296 models, we observed no HIV-1 latency reversal, at an identical dose, in PBMC isolated from the 47 participants we tested <sup>42</sup>. We observed greater *ex vivo* LRA efficacy of HDACi monotherapy, 297

relative to AZD5582. In this regard, our findings agree with a recent study that assessed a higher 298 AZD5582 concentration, although this study did not identify HDACi-AZD synergy, relative to 299 HDACi monotherapy, using higher LRA concentrations <sup>32</sup>. Interestingly, the fold-change in 300 HIV-1 RNA levels that we observed with PMA-ionomycin were orders of magnitude lower than 301 some prior studies <sup>28,32</sup>. Here, we calculated levels of HIV-1 caRNA copy number in response to 302 LRA on a per-cell basis, rather than the induction of HIV-1 transcripts on a weight basis, per µg 303 of RNA. These differences did not appear to be a function of the cell type used for latency 304 305 reversal, PBMC versus total CD4<sup>+</sup> T cells, and it remains unclear if assay technicalities or quantification methodology may contribute. 306 The use of two HDACi in our panel of ten LRA conditions increased the generalizability 307 of the findings we observed with this drug class. Similar magnitudes of boosting were observed 308 309 with RMD and PNB and suggests that class I histone deacetylase inhibition may be more relevant to this phenomenon <sup>55</sup>. LRA boosting correlated with increased histone H3 acetylation 310 in CD4<sup>+</sup> T cells but AZD-associated boosting did not recruit additional CD4s with acetylated 311 312 histone H3. HDACi monotherapy also did not increase the proportions of acetylated histone H3positive CD4s and the amount of acetylated histone H3 per cell did not meaningfully correlate 313 with the induction of HIV-1 transcription. It remains unclear if histone acetylation is correlative 314 315 or causative to virus reactivation. In the context of cellular genes, histone acetylation is not an immediate driver of the transcriptional changes observed with HDACi <sup>56</sup>. Similar magnitudes of 316 317 HIV-1 reactivation were observed with low-dose bryostatin- and AZD5582-mediated HDACi boosting and could share common mechanisms. Bryostatin and AZD5582 can activate canonical 318 319 and non-canonical NF- $\kappa$ B pathways, respectively, and the overlap in signaling with LRA boosting requires further definition. 320

321	LRA boosting, and their individual components, can have off-target effects. Whereas
322	CD69 surface expression has been proposed as a biomarker of latency reversal potency in the
323	context of PKC agonists, we found no correlation between CD69 upregulation and the magnitude
324	of latency reversal <sup>57</sup> . Low-dose bryostatin was sufficient to increase surface activation-induced
325	markers and increase cytokine production in CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells, albeit to relatively low
326	levels, either alone or in combination with HDACi. Our results confirm and extend previous
327	findings on the effects of combination LRA on T lymphocytes <sup>58</sup> . In contrast, LRA boosting
328	with AZD5582 resulted in relatively lower surface levels of CD69 and no induction of surface
329	activation markers or cytokine production in T cells. An LRA boosting approach that minimizes
330	immune modulatory effects may be more appealing as an investigational intervention.
331	The variance in HIV-1 LRA responsiveness we document, across participants and
332	replicates, has implications for future studies. Small studies may be limited in their capacity to
333	accurately quantify this variability, which increases with LRA potency. Assessments of LRA
334	activity should prioritize larger sample sizes and more than one biological replicate per
335	participant. We found that normalization of HIV-1 transcription to host gene transcription may

336 introduce additional variability. Despite HIV-1 re-activation that was superior to PMA-

ionomycin, multiply spliced HIV-1 transcription and virion production did not increase with

338 LRA boosting. Blocks to HIV-1 splicing are increasingly recognized, and here we extend those

findings to novel LRA boosting combinations <sup>23-25,59-61</sup>. Future work must focus on the post-

340 transcriptional mechanisms of HIV-1 RNA processing and inter-patient differences in LRA

341 responsiveness, which facilitate virion production during TCR agonism and treatment with

342 PMA-ionomycin and which may not be active during HIV-1 latency or LRA boosting.

343	Our study has limitations. Prior and current injection opioid use limits the peripheral
344	blood draw volumes we could obtain; this required us to prioritize experiments with a given
345	sample. The statistical significance of LRA boosting with AZD5582-containing regimens was
346	not replicated in our HEAL cohort samples and it is unclear if this relates to the variability in
347	LRA response as sample size decreases or to unrecognized differences between our cohort's
348	participants. Additional mechanisms are likely to explain how LRA boosting increases virus
349	transcription. Bryostatin may exert its HIV-1 latency reversal effects independently of PKC
350	agonism <sup>62</sup> .

The use of HIV-1 LRA at sub-maximal doses and in combination with small molecules that do not increase virus transcription, *ex vivo*, expands our understanding of how virus latency may be reversed. Follow-on studies should delineate the precise mechanisms required for efficient virus RNA processing and virion production and identify new discovery targets for future development.

356

#### 357 Acknowledgements

This work is supported by the National Institutes of Health (NIH) R61 DA047038 (NL and AT) 358 and R33 DA047038 (AT) and was facilitated by the Providence/Boston Center for AIDS 359 Research (P30AI042853) and the Harvard University Center for AIDS Research (P30AI060354). 360 361 The project described was further supported by Clinical Translational Science Award 1UL1TR002541-01 to Harvard University and Brigham and Women's Hospital from the 362 National Center for Research Resources. The content is solely the responsibility of the authors 363 and does not necessarily represent the official views of the National Center for Research 364 Resources or the National Institutes of Health. 365

#### 366 **References**

367	1.	Chun, T.W., et al. Early establishment of a pool of latently infected, resting CD4(+) T
368		cells during primary HIV-1 infection. Proceedings of the National Academy of Sciences
369		of the United States of America 95, 8869-8873 (1998).
370	2.	Whitney, J.B., et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus
371		monkeys. Nature 512, 74-77 (2014).
372	3.	Wong, J.K., et al. Recovery of replication-competent HIV despite prolonged suppression
373		of plasma viremia. Science (New York, N.Y 278, 1291-1295 (1997).
374	4.	Chun, T.W., et al. Presence of an inducible HIV-1 latent reservoir during highly active
375		antiretroviral therapy. Proceedings of the National Academy of Sciences of the United
376		States of America 94, 13193-13197 (1997).
377	5.	Finzi, D., et al. Latent infection of CD4+ T cells provides a mechanism for lifelong
378		persistence of HIV-1, even in patients on effective combination therapy. Nature medicine
379		5, 512-517 (1999).
380	6.	Siliciano, J.D., et al. Long-term follow-up studies confirm the stability of the latent
381		reservoir for HIV-1 in resting CD4+ T cells. <i>Nature medicine</i> 9, 727-728 (2003).
382	7.	Chomont, N., et al. HIV reservoir size and persistence are driven by T cell survival and
383		homeostatic proliferation. Nature medicine 15, 893-900 (2009).
384	8.	Mullins, J.I. & Frenkel, L.M. Clonal Expansion of Human Immunodeficiency Virus-
385		Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral
386		Therapy. The Journal of infectious diseases 215, S119-S127 (2017).
387	9.	Deeks, S.G., et al. International AIDS Society global scientific strategy: towards an HIV
388		cure 2016. Nature medicine (2016).

389	10.	Ferrari, G., Pollara, J., Tomaras, G.D. & Haynes, B.F. Humoral and Innate Antiviral
390		Immunity as Tools to Clear Persistent HIV Infection. The Journal of infectious diseases
391		<b>215</b> , S152-S159 (2017).
392	11.	Riley, J.L. & Montaner, L.J. Cell-Mediated Immunity to Target the Persistent Human
393		Immunodeficiency Virus Reservoir. The Journal of infectious diseases 215, S160-S171
394		(2017).
395	12.	McMahon, D.K., et al. A Phase 1/2 Randomized, Placebo-Controlled Trial of
396		Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy. The Journal
397		of infectious diseases <b>224</b> , 648-656 (2021).
398	13.	Scully, E.P., et al. Impact of Tamoxifen on Vorinostat-Induced Human
399		Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS
400		Clinical Trials Group A5366, The MOXIE Trial. Clin Infect Dis 75, 1389-1396 (2022).
401	14.	Gutierrez, C., et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on
402		antiretroviral therapy. AIDS (London, England) 30, 1385-1392 (2016).
403	15.	Archin, N.M., et al. HIV-1 expression within resting CD4+ T cells after multiple doses of
404		vorinostat. The Journal of infectious diseases 210, 728-735 (2014).
405	16.	Archin, N.M., et al. Administration of vorinostat disrupts HIV-1 latency in patients on
406		antiretroviral therapy. Nature 487, 482-485 (2012).
407	17.	Elliott, J.H., et al. Activation of HIV transcription with short-course vorinostat in HIV-
408		infected patients on suppressive antiretroviral therapy. PLoS pathogens 10, e1004473
409		(2014).
410	18.	Sogaard, O.S., et al. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
411		PLoS pathogens 11, e1005142 (2015).

412	19.	Rasmussen, T.A., et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus
413		reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2,
414		single group, clinical trial. The lancet. HIV 1, e13-21 (2014).
415	20.	Routy, J.P., et al. Valproic acid in association with highly active antiretroviral therapy for
416		reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.
417		<i>HIV medicine</i> <b>13</b> , 291-296 (2012).
418	21.	Sagot-Lerolle, N., et al. Prolonged valproic acid treatment does not reduce the size of
419		latent HIV reservoir. AIDS (London, England) 22, 1125-1129 (2008).
420	22.	Archin, N.M., et al. Interval dosing with the HDAC inhibitor vorinostat effectively
421		reverses HIV latency. The Journal of clinical investigation 127, 3126-3135 (2017).
422	23.	Yukl, S.A., et al. HIV latency in isolated patient CD4(+) T cells may be due to blocks in
423		HIV transcriptional elongation, completion, and splicing. Science translational medicine
424		<b>10</b> (2018).
425	24.	Moron-Lopez, S., et al. Characterization of the HIV-1 transcription profile after
426		romidepsin administration in ART-suppressed individuals. AIDS (London, England) 33,
427		425-431 (2019).
428	25.	Zerbato, J.M., et al. Multiply spliced HIV RNA is a predictive measure of virus
429		production ex vivo and in vivo following reversal of HIV latency. EBioMedicine 65,
430		103241 (2021).
431	26.	Martin, H.A., et al. New Assay Reveals Vast Excess of Defective over Intact HIV-1
432		Transcripts in Antiretroviral Therapy-Suppressed Individuals. Journal of virology 96,
433		e0160522 (2022).

434	27.	Rodari, A., Darcis, G. & Van Lint, C.M. The Current Status of Latency Reversing Agents
435		for HIV-1 Remission. Annu Rev Virol 8, 491-514 (2021).
436	28.	Laird, G.M., et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug
437		combinations. The Journal of clinical investigation 125, 1901-1912 (2015).
438	29.	Pache, L., et al. BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can
439		Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. Cell host &
440		<i>microbe</i> <b>18</b> , 345-353 (2015).
441	30.	Grau-Exposito, J., et al. Latency reversal agents affect differently the latent reservoir
442		present in distinct CD4+ T subpopulations. PLoS pathogens 15, e1007991 (2019).
443	31.	Pardons, M., Fromentin, R., Pagliuzza, A., Routy, J.P. & Chomont, N. Latency-
444		Reversing Agents Induce Differential Responses in Distinct Memory CD4 T Cell Subsets
445		in Individuals on Antiretroviral Therapy. Cell Rep 29, 2783-2795 e2785 (2019).
446	32.	Dai, W., et al. Genome-wide CRISPR screens identify combinations of candidate latency
447		reversing agents for targeting the latent HIV-1 reservoir. Science translational medicine
448		14, eabh3351 (2022).
449	33.	Gupta, V. & Dixit, N.M. Trade-off between synergy and efficacy in combinations of
450		HIV-1 latency-reversing agents. PLoS computational biology 14, e1006004 (2018).
451	34.	Edelman, E.J., et al. Receipt of opioid analgesics by HIV-infected and uninfected
452		patients. J Gen Intern Med 28, 82-90 (2013).
453	35.	Reddon, H., et al. Methadone maintenance therapy decreases the rate of antiretroviral
454		therapy discontinuation among HIV-positive illicit drug users. AIDS Behav 18, 740-746
455		(2014).

456	36.	Tavitian-Exley, I., Vickerman, P., Bastos, F.I. & Boily, M.C. Influence of different drugs
457		on HIV risk in people who inject: systematic review and meta-analysis. Addiction 110,
458		572-584 (2015).

- 459 37. Green, T.C., McGowan, S.K., Yokell, M.A., Pouget, E.R. & Rich, J.D. HIV infection and
- 460 risk of overdose: a systematic review and meta-analysis. *AIDS (London, England)* **26**,

461 403-417 (2012).

462 38. Borner, C., Kraus, J., Bedini, A., Schraven, B. & Hollt, V. T-cell receptor/CD28-

463 mediated activation of human T lymphocytes induces expression of functional mu-opioid

464 receptors. *Mol Pharmacol* **74**, 496-504 (2008).

- 39. Borner, C., *et al.* Mechanisms of opioid-mediated inhibition of human T cell receptor
  signaling. *J Immunol* 183, 882-889 (2009).
- 467 40. Mbonye, U. & Karn, J. Transcriptional control of HIV latency: Cellular signaling
- 468 pathways, epigenetics, happenstance and the hope for a cure. *Virology* (2014).
- 469 41. Basukala, B., *et al.* Virally Suppressed People Living with HIV Who Use Opioids Have
- 470 Diminished Latency Reversal. *Viruses* **15**(2023).
- 471 42. Nixon, C.C., *et al.* Systemic HIV and SIV latency reversal via non-canonical NF-kappaB
  472 signalling in vivo. *Nature* 578, 160-165 (2020).
- 473 43. Reiss, S., *et al.* Comparative analysis of activation induced marker (AIM) assays for
- 474 sensitive identification of antigen-specific CD4 T cells. *PLoS ONE* **12**, e0186998 (2017).
- 475 44. Ceriani, C., et al. Defining stable reference genes in HIV latency reversal experiments.
- 476 *Journal of virology* **95**(2021).

477	45.	Gandhi, R.T., et al. Levels of HIV-1 persistence on antiretroviral therapy are not
478		associated with markers of inflammation or activation. PLoS pathogens 13, e1006285
479		(2017).
480	46.	Procopio, F.A., et al. A Novel Assay to Measure the Magnitude of the Inducible Viral
481		Reservoir in HIV-infected Individuals. EBioMedicine 2, 874-883 (2015).
482	47.	Mehandru, S., et al. Behavioural, Mucosal and Systemic Immune Parameters in HIV-
483		infected and Uninfected Injection Drug Users. J Addict Res Ther 6, 1-8 (2015).
484	48.	Deren, S., Cleland, C.M., Lee, H., Mehandru, S. & Markowitz, M. Brief Report: The
485		Relationship Between Injection Drug Use Risk Behaviors and Markers of Immune
486		Activation. Journal of acquired immune deficiency syndromes (1999) 75, e8-e12 (2017).
487	49.	Khoury, G., et al. Human Immunodeficiency Virus Persistence and T-Cell Activation in
488		Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected
489		Individuals Receiving Suppressive Antiretroviral Therapy. The Journal of infectious
490		<i>diseases</i> <b>215</b> , 911-919 (2017).
491	50.	Massanella, M., Fromentin, R. & Chomont, N. Residual inflammation and viral
492		reservoirs: alliance against an HIV cure. Current opinion in HIV and AIDS 11, 234-241
493		(2016).
494	51.	Ruggiero, A., et al. During Stably Suppressive Antiretroviral Therapy Integrated HIV-1
495		DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells
496		Expressing HLA-DR/DP/DQ. EBioMedicine 2, 1153-1159 (2015).
497	52.	Cockerham, L.R., et al. CD4+ and CD8+ T cell activation are associated with HIV DNA
498		in resting CD4+ T cells. PLoS ONE 9, e110731 (2014).

499	53.	Spencer, M.R., Minino, A.M. & Warner, M. Drug Overdose Deaths in the United States,
500		2001-2021. NCHS Data Brief, 1-8 (2022).
501	54.	Bachmann, N., et al. Determinants of HIV-1 reservoir size and long-term dynamics
502		during suppressive ART. Nat Commun 10, 3193 (2019).
503	55.	Milazzo, G., et al. Histone Deacetylases (HDACs): Evolution, Specificity, Role in
504		Transcriptional Complexes, and Pharmacological Actionability. Genes (Basel) 11(2020).
505	56.	Halsall, J.A., Turan, N., Wiersma, M. & Turner, B.M. Cells adapt to the epigenomic
506		disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-
507		mediated transcriptional response. Epigenetics Chromatin 8, 29 (2015).
508	57.	Marsden, M.D., et al. In vivo activation of latent HIV with a synthetic bryostatin analog
509		effects both latent cell "kick" and "kill" in strategy for virus eradication. PLoS pathogens
510		<b>13</b> , e1006575 (2017).
511	58.	Walker-Sperling, V.E., Pohlmeyer, C.W., Tarwater, P.M. & Blankson, J.N. The Effect of
512		Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill
513		Strategies for Human Immunodeficiency Virus Eradication. EBioMedicine 8, 217-229
514		(2016).
515	59.	Wedrychowski, A., et al. Transcriptomic Signatures of Human Immunodeficiency Virus
516		Post-Treatment Control. Journal of virology 97, e0125422 (2023).
517	60.	Moron-Lopez, S., et al. Human splice factors contribute to latent HIV infection in
518		primary cell models and blood CD4+ T cells from ART-treated individuals. PLoS
519		pathogens 16, e1009060 (2020).

	520	61.	Mota, T.M., e	et al. Integrated	Assessment of V	Viral Transcrip	tion, Antigen	Presentation.
--	-----	-----	---------------	-------------------	-----------------	-----------------	---------------	---------------

- and CD8(+) T Cell Function Reveals Multiple Limitations of Class I-Selective Histone
- 522 Deacetylase Inhibitors during HIV-1 Latency Reversal. *Journal of virology* **94**(2020).
- 523 62. Mbonye, U., Leskov, K., Shukla, M., Valadkhan, S. & Karn, J. Biogenesis of P-TEFb in
- 524 CD4+ T cells to reverse HIV latency is mediated by protein kinase C (PKC)-independent
- signaling pathways. *PLoS pathogens* **17**, e1009581 (2021).
- 526 63. McLellan, A.T., *et al.* The Fifth Edition of the Addiction Severity Index. *J Subst Abuse*
- 527 *Treat* **9**, 199-213 (1992).
- 528 64. Institute of Behavioral Research. Texas Christian University Drug Screen 5. Fort Worth:
- 529 Texas Christian University, Institute of Behavioral Research (2020)
- 530 (<u>https://ibr.tcu.edu/forms/tcu-drug-screen/</u>).
- 65. Malnati, M.S., *et al.* A universal real-time PCR assay for the quantification of group-M
- 532 HIV-1 proviral load. *Nature protocols* **3**, 1240-1248 (2008).
- 533 66. Bruner, K.M., et al. A quantitative approach for measuring the reservoir of latent HIV-1
- 534 proviruses. *Nature* **566**, 120-125 (2019).
- 535
- 536
- 537
- 538
- 539
- 540
- 541
- 542

#### 543 Table 1. OPHION Participant Characteristics

	Coh	ort	
Characteristic	Non-Opioid	Opioid	Total*
Participants, N	12	24	36
Age			
Median (IQR <sup>†</sup> )	56 (50-61)	61 (55-65)	59 (54-65)
Sex			
Male N (%)	7 (58%)	17 (71%)	24 (67%)
Race			
Black N (%)	10 (83%)	6 (25%)	16 (44%)
White N (%)	2 (17%)	9 (38%)	11 (31%)
Hispanic/Latino** N (%)	0	2 (8%)	2 (6%)
American Indian N (%)	0	1 (4%)	1 (3%)
Declined/NA	0	6 (25%)	6 (17%)
Ethnicity			
Non-Hispanic N (%)	11 (92%)	13 (54%)	24 (67%)
Hispanic N (%)	1 (8%)	11 (46%)	12 (33%)
Duration of ART (months)			
Median (IQR)	162 (106-204)	136 (91-173)	144 (97-179
Duration of viral suppression (months)			
Median (IQR)	69.5 (38-91)	79 (51-94)	75 (44-93)
			*Participants may

547 "Declined/Not Available."

#### 553 Figure Legends

554

555	Figure 1. HIV-1 reservoir size and intactness during opioid use. Quantifications were performed
556	on participants who used (n=24) or did not use (n=12) opioids. (a) HIV-1 persistence measures
557	in participants with (blue circles) and without (yellow circles) opioid use are shown. Data are
558	displayed on a logarithmic y-axis scale; DNA and RNA was extracted from 5 million PBMC.
559	Intact DNA was quantified with the IPDA assay. Mean values $\pm$ standard errors of the mean
560	(SEM) are shown. (b) 5' and 3' genomic deletions as a function of opioid use, mean values $\pm$
561	95% CIs are displayed, (c) Opioid subgroup analysis. The reservoir size of intact, 5' deleted, and
562	3' deleted or hypermutated regions are shown. (d) The proportion of intact genomes as a function
563	of DNA copies and opioid use subgroup. Cohort 1, injection opioid use; cohort 2, prescribed oral
564	opioids for pain; cohort 3, methadone; cohort 4, suboxone; cohort 5, no opioid use.

565

566 Figure 2. HIV-1 latency reversal in OPHION participants. HIV-1 caRNA levels were quantified after 24-hour incubations using 5 million PBMC and compared to a no-drug DMSO-containing 567 568 condition. Mean values and the 95% CIs are shown. (a) Combined data showing LRA responses 569 in thirty-six total participants with (blue circles) or without (yellow circles) opioid use. Data 570 from (a) was dichotomized by (b) opioid use, (c) sex (light purple circles, male; light grey 571 circles, female), and (d) race (light green circles, Black and American Indian; dark green circles, 572 white). (e) Opioid-use subgroup analysis highlighting LRA response to αCD3/αCD28 beads 573 from (a), as a function of opioid use subgroup. Means and SEM are shown. Dotted horizontal line denotes a fold-change of 1. \*p<0.05, \*\* p<0.01, \*\*\* p<0.001, and \*\*\*\* p<0.0001 for LRA 574 combinations, corrected for multiple comparisons. aCD3/aCD28, anti-CD3 anti-CD28 575

superparamagnetic beads; RMD, romidepsin; PNB, panobinostat; R, RMD 20nM; P, PNB
30nM; B, bryostatin 1nM; A, AZD5582 100nM.

578

Figure 3. Immune activation and cytokine induction during *ex vivo* LRA boosting. (a) Example 579 plots of OX40<sup>+</sup>PD-L1<sup>+</sup>, OX40<sup>+</sup>CD25<sup>+</sup>, and CD69<sup>+</sup>CD40L<sup>+</sup> expression from live CD4<sup>+</sup> T cells in 580 PBMC samples incubated with DMSO control or an aCD3/aCD28 bead positive control for 18 581 hours, (b) Violin plots of surface activation-induced marker (AIM) response as a function of 582 583 LRA, Results across three highly sensitive AIM assays for OPHION participants' samples (n=36) are shown for comparison, (c) Quantification of LRA-induced surface CD69 expression 584 in live total CD4<sup>+</sup> T cells (n=36). Intracellular production of the cytokines TNF- $\alpha$ , IFN- $\gamma$ , and IL-585 586 2 during LRA exposure in (d) live CD4<sup>+</sup> and (e) CD8<sup>+</sup> T cells (n=36). Violin plot median values are indicated by a solid black line; quartiles are shown with a dotted line. LRA conditions 587 without visible bars represent values < 0.1% of cells. \*p< 0.05, \*\*\* p< 0.001, and \*\*\*\* p< 0.0001588 589 for LRA combinations, corrected for multiple comparisons. RMD, romidepsin; PNB, 590 panobinostat; R, RMD 20nM; P, PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM. 591 592 Figure 4. Histone H3 acetylation patterns during LRA exposure. (a) Violin plots showing the proportion of live total CD4<sup>+</sup> T cells with acetylated histone H3, assessed by flow cytometry, (b) 593 Violin plot of mean fluorescence intensity (MFI) of acetylated histone H3 per live CD4<sup>+</sup> T cell. 594 Scatter plots of acetylated histone H3 levels per CD4 as a function of HIV-1 transcription in 595 response to (c) RMD and PNB monotherapy, (d) LRA boosting with HDACi and AZD5582, and 596 597 (e) HDACi in combination with low-dose bryostatin are shown. Acetylated histone levels and HIV-1 reactivation with the combinations of HDACi and bryostatin were moderately positively 598

correlated (r=.25, p=.04). Violin plot median values are indicated by a solid black line; quartiles
are shown with a dotted line.

601

602	Figure 5. Comparative analysis of LRA boosting effects in PBMC and CD4 <sup>+</sup> T cells.
603	Leukapheresis samples from HEAL cohort participants (n=11) were used to assess HIV-1
604	unspliced caRNA levels during (a) low-dose bryostatin-based and (b) AZD5582-based LRA
605	boosting combinations, when compared to PMA-ionomycin. Data are presented as means $\pm$
606	SEM. Circle color is used to denote a given HEAL participant across Figure panels. (c) Absolute
607	HIV-1 unspliced caRNA levels in parallel PBMC and CD4 <sup>+</sup> T cell LRA exposures. PBMC and
608	CD4 results are separated by a vertical dotted line. (d) Representation of the data in (c) as fold-
609	change in HIV-1 caRNA levels. (e) Corresponding HIV-1 RNA levels from culture supernatants.
610	(f) Multiply spliced HIV-1 RNA levels as determined in a modified TILDA assay, comparing
611	RMD-bryostatin combinations at two bryostatin concentrations to PMA-ionomycin. (g)
612	Combined OPHION and HEAL participant results (n=47) that summarize PBMC LRA boosting
613	responses, for LRA conditions common to both datasets. Results from OPHION participant
614	samples, carried over from Fig. 2a, are shown in grey circles. HEAL participant results are
615	shown in color. *p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, corrected for multiple
616	comparisons. NDC, no-drug control, contains 0.2% DMSO; PMAi, PMA with ionomycin; RMD,
617	romidepsin; PNB, panobinostat; R, RMD 20nM; P, PNB 30nM; B, bryostatin 1nM; A,
618	AZD5582 100nM.
619	

620

621

#### 622 Supplementary Figures Legends

Supplementary Figure 1. Substance use in the OPHION cohort. We assessed substance 623 use by (a) clinical urine toxicology testing and (b) self-reported substance use questionnaires. 624 Substance use results are separated by cohort groups by participant ID. Red squares indicate the 625 presence of that substance in a urine sample; unavailable data were marked with "X" in a gray 626 box. An expanded opiate panel was performed to assess for the presence of different opiate 627 formulations. Color squares in panel b reflect any reported use by participants in the last 30 days. 628 The numbers inside a given box indicate the number of days used this substance was reported to 629 630 be used in the last 30 days. Gradient of color from blue to red indicate increasing report of use 631 whereas white indicates no use. Concomitant use of alcohol, tobacco, marijuana, and gabapentin in the OPHION cohort was common. \*all fentanyl measures were confirmed by follow-on 632 633 quantification. Participants in the buprenorphine and methadone groups reported daily use of the 634 respective medication in the 30 days prior, whereas participants taking opioids for chronic pain took opioids for 27-30 days in the 30 days preceding their enrollment in OPHION. 75% (N=3/4) 635 636 of active injection users had urine toxicology screens positive for cocaine corresponding with self-report; all three reported smoking cocaine in the prior 30 days to specimen collection. One 637 of twelve participants in the methadone use group and 2/12 in the non-opiate use group also has 638 639 urine toxicology screens positive for cocaine. All active injection opioid users reported using multiple drugs on the same day in the last 30 days compared to 1/12 participants in non-opioid 640 use group and 10/20 participants in methadone, buprenorphine and prescription opiate use 641 groups combined. N=3/4 active injection opioid users reported smoking marijuana in the last 30 642 days. 6 and 8 participants about the 12 participants in opioid use groups had urine toxicology 643 screens positive for benzodiazepines and gabapentin; all but 1 in both cases reported that this 644

645	substance was prescribed. No participant had urine toxicology screens positive for amphetamines
646	or barbiturates. All participants injecting opioids used tobacco in the preceding 30 days and,
647	overall, 23 of 36 OPHION participants used tobacco within the month prior to their blood
648	collection. 25% (N=6/24) of opioid use participants consumed alcohol in last 30 days compared
649	to 58% (7/12) in the control group.
650	
651	Supplementary Figure 2. HIV-1 LRA boosting response in the OPHION cohort by ethnicity.
652	HIV-1 fold-increase in unspliced RNA transcription plotted as a function of self-reported
653	Hispanic (dark purple circles) or non-Hispanic (light blue circles) ethnicity.
654	
655	Supplementary Figure 3. Flow cytometry gating strategies. Representative intracellular
656	cytokine staining plots for (a) control and (b) $\alpha$ CD3/ $\alpha$ CD28 bead-exposed PBMC are shown. (c)
657	AIM assay and gating strategy and representative flow plots for control and $\alpha$ CD3/ $\alpha$ CD28 bead-
658	exposed PBMC.
659	

Supplementary Figure 4. LRA-induced immune activation as a function of opioid use. Results 660 obtained with the (a) OX40/PD-L1, (b) OX40/CD25, and (c) CD69/CD40L AIM assays are 661 662 reported for all ten conditions in the LRA panel, where samples from participants with (blue circles) and without (yellow circles) opioid use are shown. Data are represented as means  $\pm 95\%$ 663 CIs. The highest measured levels in OX40/PDL1 assay with bryostatin 1nM, R+B, and P+B are 664 the same non-opioid-using participant. (d) Individual data points for CD69<sup>+</sup> live total CD4<sup>+</sup> T 665 cells, as a function of opioid use. (e) Comparative hierarchies of intracellular cytokine 666 production in CD4<sup>+</sup> and CD8<sup>+</sup> T cells exposed to  $\alpha$ CD3/ $\alpha$ CD28 beads. Data displayed in these 667

panels are identical to the data values shown in Main Fig. 3. \*p<0.05, \*\* p<0.01, \*\*\*\* p<0.0001,</li>
corrected for multiple comparisons. TNF, tumor necrosis factor-alpha; IFN, interferon-gamma;
IL-2, interleukin-2; CD4, CD4<sup>+</sup> T cells; CD8, CD8<sup>+</sup> T cells.

671

**Supplementary Figure 5.** Intracellular cytokine production, as a function of opioid use. Using the same data displayed in Main Fig. 3, here we show individual data points, labelled as samples from participants with (blue circles) and without (yellow circles) opioid use. CD4<sup>+</sup> T cell production of (a) TNF- $\alpha$ , (b) IL-2, and (c) IFN- $\gamma$ . CD8+ T cell production of (d) TNF- $\alpha$ , (e) IFN- $\gamma$ , (f) IL-2. No significant differences in cytokine production were observed by opioid use.

Supplementary Figure 6. Histone acetylation effects during LRA boosting, as a function of
opioid use. Using the same data displayed in Main Fig. 4, here we show individual data points,
labelled as samples from participants with (blue circles) and without (yellow circles) opioid use.
(a) The proportion of live total CD4<sup>+</sup> T cells with acetylated histone H3, assessed by flow
cytometry, (b) Mean fluorescence intensity (MFI) of acetylated histone H3 per live total CD4<sup>+</sup> T
cells.

684

Supplementary Figure 7. The effects of LRA boosting on human reference gene transcription.
Using leukapheresis samples from HEAL participants (n=9), we assessed and compared foldchanges in transcription of three host genes: (a) IPO8, (b) TBP, and (c) UBE2D2. Reference
gene multiplexing was validated for (d) TBP and (e) UBE2D2 quantifications. The rationale to
study these three reference genes is as follows. IPO8 transcription is used as an internal control
by the AIDS Clinical Trials Group's Virology Specialty Laboratories to measure RNA integrity

691	in a dichotomous way. IPO8 Ct values >27 are used to suggest degradation of cellular samples in
692	storage, and samples with IPO8 Ct >27 do not report HIV-1 RNA values. Recent work by
693	Nancie Archin at the UNC HIV Cure Center identified TBP and UBE2D2 as two of the more
694	stable host genes during LRA exposures, which included PMA, AZD5582, and HDACi, among a
695	panel of eight LRA.
696	
697	Supplementary Figure 8. Variance in LRA response. (a) Magnitude of HIV-1 caRNA
698	transcription fold-changes in biological replicate LRA experiments performed with HEAL
699	leukapheresis samples, derived from the data displayed in Main Fig 5a-c, (b) Box and whiskers
700	plot displaying the data of Fig. 5g as the mean (solid black horizontal line), inter-quartile range
701	$(25^{th} - 75^{th} \text{ percentiles denoted as the borders of the vertical rectangle})$ , and $5^{th}-95^{th}$ percentiles
702	(whiskers, error bars). Values below and above the whiskers are shown as individual data points.
703	PMA-iono, PMA with ionomycin; RMD, romidepsin; PNB, panobinostat; R, RMD 20nM; P,
704	PNB 30nM; B, bryostatin 1nM; A, AZD5582 100nM.
705	
706	Supplementary Tables
707	Supplementary Table 1 – Breakdown of OPHION cohort into opioid use subgroups
708	Supplementary Table 2 – HEAL Participant Characteristics
709	
710	
711	
712	
713	

#### 714 **Online Methods**

#### 715 Study Design and Clinical Cohorts

The Opioids, HIV, and Translation (OPHION) study is a prospective cohort study of participants 716 living with HIV on suppressive antiretroviral therapy recruited from Boston Medical Center 717 which serves one of the largest populations of people living with HIV (PLWH) in Massachusetts, 718 including a disproportionately large number of persons with opioid and substance use disorders. 719 Eligible PLWH were required to currently be on antiretroviral therapy and virologically 720 721 suppressed (defined as undetectable plasma HIV-1 RNA or <20 copies/ml) for a minimum of 12 months prior to enrollment. Individuals were recruited into 1 of 5 cohorts: (1) active injection 722 opioid use, defined as self-report on injecting opioids at least once per week, (2) Methadone 723 724 maintenance therapy for at least 3 months, (3) buprenorphine-naloxone therapy for at least 3 months, (4) Prescription oral opioid use for at least 6 months or (5) No opioid use within the past 725 726 1 year representing a control cohort. Eligibility into each of the five cohorts was confirmed with 727 a urine toxicology performed at the BMC central laboratory, which includes evaluation for urine drug metabolites including opiates and non-opioid substances as well as an expanded opioid 728 panel which included fentanyl or norfentanyl metabolites. Exclusionary criteria included ongoing 729 730 immunosuppression and pregnancy; patients who reported injecting non-opioid substances were 731 also not eligible. Once consented and enrolled, each participant underwent blood collection for same day PBMC extraction as well as urine collection for gabapentin and benzodiazepine 732 metabolites. Participants also completed an extensive survey on their current and prior substance 733 use (including alcohol and tobacco use) based the addiction severity index (ASI)<sup>63</sup> and Texas 734 Christian University (TCU) drug screen <sup>64</sup>. HIV and other clinical information including ART 735

treatment history, duration of virologic suppression and comorbidity status including hepatitis C
and B were abstracted from the medical record.

The HIV Eradication and Latency (HEAL) Cohort is a longitudinal biorepository study of 738 participants with HIV. Inclusion criteria for HEAL participants in this study were 1) ART-treated 739 participants with HIV-1 who were virologically suppressed, defined as plasma HIV-1 RNA less 740 than assay (most commonly less than 20 copies/mL, without blips) for >1 year and 2) had 741 sufficient available amounts of cryopreserved PBMC for the proposed analyses. These cohort 742 743 studies are performed in accordance with the principles of the Declaration of Helsinki. The institutional review boards at Boston Medical Center and Brigham and Women's Hospital (Mass 744 General Brigham Human Research Committee) approved the study protocols. Written informed 745 746 consent was obtained from all participants. Experimenters were blinded to all clinical data and to OPHION subgroup assignments. 747

748

#### 749 Quantification of HIV-1 persistence markers

Genomic DNA and total RNA were isolated from approximately 5x10<sup>6</sup> peripheral blood 750 mononuclear cells (PBMC) or total CD4<sup>+</sup> T cells (AllPrep DNA/RNA kit, Qiagen). Total HIV-1 751 752 DNA and unspliced cell-associated RNA (caRNA) levels were quantified in triplicate by realtime PCR as previously described, modified to include Taqman Universal Mastermix (DNA) or 753 Taqman Fast Virus 1-Step Mastermix (RNA)<sup>65</sup>. HIV-1 quantifications used forward primer 5'-754 TACTGACGCTCTCGCACC-3', reverse primer 5'-TCTCGACGCAGGACTCG-3', and probe 755 5' FAM-CTCTCTCCTTCTAGCCTC-MGB 3' (ThermoFisher Scientific). DNA cycling 756 conditions in a total reaction volume of 25µL were 95°C for 15 min followed by 40 cycles of 757 95°C for 15 sec and 60°C for 1 min. RNA cycling conditions in a total reaction volume of 20µL 758

759	were 55°C for 15 min, 95°C for 20 sec, followed by 40 cycles of 95°C for 3 sec and 60°C for 30
760	sec. Approximately 500ng of genomic DNA were assessed per well. The limits of quantification
761	for total HIV-1 DNA and unspliced caRNA were 1 and 3 copies per reaction, respectively.
762	Limits of detection were calculated per timepoint and participant sample, considering the
763	average number of copies detected across triplicate measurements. Cell input numbers were
764	quantified by human genome equivalents of CCR5 DNA using forward primer 5'-
765	ATGATTCCTGGGAGAGACGC-3', reverse primer 5'-AGCCAGGACGGTCACCTT-3', and
766	probe 5' FAM-CTCTCTCCTTCTAGCCTC-MGB 3' (ThermoFisher Scientific) as described <sup>65</sup> .
767	
768	Intact proviral DNA assay
769	HIV-1 DNA from isolated PBMC DNA was measured using the intact proviral DNA assay
770	(IPDA) <sup>66</sup> . Briefly, a multiplex droplet digital PCR assay was performed using primer and probe
771	sets targeting the Psi packaging signal and env regions of the HIV-1 genome using 700 ng DNA
772	per well. Intact provirus genomes were indicated in double positive droplets whereas incomplete
773	genomes were single positive and classified as either 5' (Psi-/env+) or 3' (Psi+/env-) deletions.
774	Quantified proviral sequences were normalized to cell number reference gene RPP30 and
775	expressed as copies per million PBMC. Data was generated using the Bio-Rad QX200 Droplet
776	Digital PCR system and analyzed using QuantaSoft Data Analysis Software.
777	
778	Multiply spliced HIV-1 transcripts
779	To measure the frequency of total CD4 <sup>+</sup> T cells with inducible multiply spliced HIV-1 RNA, we

performed the TILDA assay, as previously described, with two modifications <sup>46</sup>. First, to reduce

the 95% CIs around our frequency estimates, we used 36 x  $10^6$  cells/mL as our first dilution,

782	rather than the 18 x 10 <sup>6</sup> cells/mL used in Procopio, et al. Second, to harmonize our PMA-
783	ionomycin concentrations with LRA experiments, we reduced the PMA concentration from its
784	original 100 ng/mL to 50ng/mL in our TILDA assays. The duration of virologic suppression in
785	our HEAL participants was similar to previously reported participants <sup>46</sup> .
786	
787	Reference gene quantification
788	Extracted PBMC RNA was used to quantify transcription levels of three host genes, IPO8, TBP,
789	and UBE2D2, typically immediately after the loading of HIV-1 caRNA qPCR plates was
790	complete. IPO8 quantifications used forward primer 5'- CCTTTGTACAACAGAAGGCAC -3',
791	reverse primer 5'- TGCACGTCTCAGGTTTTTGC -3', and probe 5' FAM-
792	TCCGCATAAATCCATTGATTCTGC -MGB 3' (ThermoFisher Scientific); TBP
793	quantifications used forward primer 5'- CAGTGAATCTTGGTTGTAAACTTGA -3', reverse
794	primer 5'- TCGTGGCTCTCTTATCCTCAT -3', and probe 5' FAM-
795	CGCAGCAAACCGCTTGGGATTAT -MGB 3' (ThermoFisher Scientific); and UBE2D2
796	quantifications used forward primer 5'- GTACTCTTGTCCATCTGTTCTCTG -3', reverse
797	primer 5'- CCATTCCCGAGCTATTCTGTT -3', and probe 5' VIC-
798	CCGAGCAATCTCAGGCACTAAAGGA -MGB 3' (ThermoFisher Scientific). To generate
799	IPO8 standards, we cloned a fragment corresponding to nucleotides 3636-3707 of IPO8 mRNA
800	(Sequence ID NM_006390.4) into a pCR4-TOPO vector (ThermoFisher Scientific, Cat. No.
801	K458001). To generate TBP standards, a fragment corresponding to nucleotides 649-1037 of
802	TBP mRNA (Sequence ID NM_003194) was cloned into a pCR4-TOPO vector. To generate
803	UBE2D2 standards, a fragment corresponding to nucleotides 729-1164 of UBE2D2 mRNA
804	(Sequence ID NM_181838.2) was cloned into a pCR4-TOPO vector. Reference gene RNA was

805	synthesized using T3 Megascript Kit (ThermoFisher Cat. No. AM1333 and cleaned (RNease
806	MinElute Cleanup Kit, Qiagen, Cat. No. 74204) before serially diluting across a range of $10^6 -$
807	10 <sup>3</sup> copies per well. After TBP and UBE2D2 standards were individually validated, TBP (T)
808	and UBE2D2 (U) RNA were diluted separately and aliquoted together as one set of multiplex
809	standards. T and U standards were validated to demonstrate overlap of individual and
810	multiplexed standards curves. The assay was optimized to run all host gene standards and
811	samples on one 96-well reaction plate in a total reaction volume of $20\mu L$ using cycling
812	conditions of 55°C for 5 min, 95°C for 20 sec, followed by 40 cycles of 95°C for 3 sec and 56°C
813	for 30 sec. Reference gene standards and samples were run in duplicate. IPO8, TBP, and
814	UBE2D2 RNA copies per million PBMC were calculated by dividing copies per total sample by
815	number of cells per sample, determined by CCR5 quantification, and normalized to $1 \times 10^{6}$ cells.
816	Fold changes were calculated by dividing the RNA copy number obtained per million PBMC for
817	each LRA condition by the 0.2% DMSO control condition's reference gene RNA copies/million
818	PBMC.

819

#### 820 HIV-1 latency reversal

OPHION and HEAL participant peripheral blood mononuclear cells (PBMC) were isolated from large volume (90 – 180cc) peripheral blood or leukapheresis collections by density centrifugation and cryopreserved. Cryopreserved PBMC were thawed, pelleted, and transferred to RPMI media supplemented with 10% fetal bovine serum, 2  $\mu$ M raltegravir, and 2  $\mu$ M tenofovir (R10 + TDF/RAL) at a concentration of 1x10<sup>6</sup> cells/mL. Cells were rested in a humidified CO<sub>2</sub> incubator at 37°C for three hours (hrs). After 3hrs, cells were counted and assessed for viability. For CD4<sup>+</sup> T cell experiments, PBMC were pelleted, resuspended in EasySep Buffer (StemCell

828	Technologies, cat. no. 20144), and isolated with EasySep Human CD4 <sup>+</sup> T Cell Enrichment Kit
829	(StemCell cat. no. 19052) per the manufacturer's instructions. A total of $5 \times 10^6$ PBMC, or total
830	CD4 <sup>+</sup> T cells, were aliquoted into 5mL of fresh R10 + RAL/TDF in 6-well sterile cell culture
831	plates. Cells were incubated in the presence or absence of the following LRA conditions: 0.2%
832	DMSO, 1:1 $\alpha$ CD3/ $\alpha$ CD28 beads (Life Technologies, cat. no. 11131D) to cells with 30 U/mL IL-
833	2 (R&D Systems, cat. no. 202-IL-500), romidepsin 20 nM (Sigma , cat. no. SML1175),
834	panobinostat 30nM (Sigma, cat. no. SML3060), bryostatin-1 1nM (Sigma, cat. no. B7431),
835	AZD5582 100nM (ChemieTek, cat. no. CT-A5582), romidepsin 20 nM plus bryostatin-1 1nM,
836	panobinostat 30nM plus bryostatin-1 1nM 100nM, romidepsin 20 nM plus AZD5582 100nM,
837	panobinostat 30nM plus AZD5582 100nM, and phorbol 12-myristate 13-acetate (PMA)
838	50ng/mL (Sigma, cat. no. P1585) in combination with ionomycin 1µM (Sigma, cat. no. I9657).
839	To provide a known positive control for subsequent immunology assessments, $\alpha CD3/\alpha CD28$
840	beads were used with OPHION samples. Cultures were incubated at 37°C for 24 hours. After 24
841	hours, cells were prepared for nucleic acid extractions.
842	

#### 843 Activation Induced Marker (AIM) assay

AIM assays were performed as previously described <sup>43</sup>. Briefly, cryopreserved PBMC were thawed, washed, resuspended in R10, and rested for 3 hours at 37°C. Following the 3-hour rest interval, the appropriate number of cells were transferred to a 48-well plate and subsequently treated with CD40 blocking antibody (Miltenyi Biotec, cat. no. 130-094-133) for a final concentration of 0.5ug/mL for 15 minutes at 37°C. Cells were incubated in the presence or absence of our 10-LRA panel, as previously described. After an 18hr incubation, cells were harvested and stained for 50 minutes at 4°C with the surface staining monoclonal antibodies

851	(mAb); (PD-L1-PE/Cy7 (Biolegend, cat. no. 329717), CD40L-PE (BD Biosciences [BD], cat.
852	no. 561720), OX40-APC (BD cat. no. 563473), CD69-BV650 (Biolegend cat. no. 310933),
853	CD3-BV605 (Biolegend cat. no. 317322), CD4-BV421 (BD cat. no. 562424), CD8-PerCp-Cy5.5
854	(BD cat. no. 560662), CD25- BUV395 (BD cat. no. 564034) and LIVE/DEAD Near-IR stain
855	(ThermoFisher cat. no. L34975), washed, fixed and permeabilized (BD cytofix fixation buffer,
856	cat. no. 554655), and then stained for 30 minutes at 4°C with intracellular mAb Acetyl-histone
857	H3-Alexa Fluor 488 (Cell Signaling Technology, cat. no. 9683S) in 1x perm/wash buffer (BD,
858	cat. no. 554723). The cells were washed and fixed (BD cytofix fixation buffer, cat. no. 554655)
859	prior to flow cytometry analysis.
860	

#### 861 Intracellular cytokine staining

862 Cryopreserved PBMC were thawed, washed, resuspended in RPMI + 10% FBS (R10), and

rested for 3 hours at 37°C. Following the 3-hour rest interval, the appropriate number of cells

were transferred to a 48-well plate and incubated for 2 hrs with our panel of 10 LRA. Following

this 2-hour incubation period, GolgiPlug (BD, cat. no. 555029) and GolgiStop (BD, cat. no.

see 554724) were added to each condition at a concentration of 1:1000 and 6:10000 respectively,

then incubated at 37°C for an additional 16 hrs. Cells were harvested, pelleted, resuspended,

stained for 20 minutes at 4°C with surface staining mAb (CD3-BV605, CD4-BV421, CD8-

869 PerCp-Cy5.5 and LIVE/DEAD Near-IR stain), fixed and permeabilized as described above, and

then stained for 30 minutes at 4°C with the intracellular mAb TNF-α- PE/Dazzle-594 (Biolegend

cat. no. 502946), IL-2- PE/Cy7 (BD cat. no. 560707) and IFN-γ- BV510 (Biolegend cat. no.

502544). PBMC were washed and fixed in (BD cytofix fixation buffer, cat. no. 554655) prior to

873 flow cytometry analysis, as described above.

874

#### 875 Flow cytometry

876 Cells were acquired on a BD LSRFortessa using FACSDiva. Analysis was performed using


FlowJo software versions 10.6.2 (Treestar, Versions 10 for Mac). Representative gating

878 strategies can be found in the supplemental figures.

879

#### 880 Statistical analysis

Statistical analyses were performed using GraphPad Prism 9 for macOS. Means, medians, 95% 881 confidence intervals, and standard errors of the mean were calculated. The pre-specified primary 882 outcome of OPHION was a comparison of log<sub>10</sub> PBMC HIV-1 caRNA levels between 883 884 participants who use and do not use opioids. The pre-specified outcome for OPHION latency reversal experiments was the difference in HIV-1 caRNA levels between LRA treatment groups 885 and across opioid use groups. To assess for changes in HIV-1 caRNA, we performed Kruskal-886 887 Wallis testing of all participants together for each of the LRAs with Dunn's multiple comparison test, comparing the mean rank of each LRA condition with the mean rank of every other LRA 888 condition. An identical approach was taken with a series of exploratory analyses with OPHION 889 890 participant samples that assessed histone acetylation, surface activation, and intracellular 891 cytokine production, and with the exploratory statistical analyses performed on experiments with 892 HEAL participant samples.



00

 $\mathcal{O}$ 


is version pos

bas gran


0

carna intactona


rg/101101/2023.05.26.23290 er review) is the author/funde It is made available under a







d.



log<sub>10</sub> HIV-1 copies 10<sup>6</sup> PBMC

3:


01 TOtal DNA

a.

Cohort

- Intact
- 3' deletion/hypermut
- 5' deletion


Intact 3' deletion/hypermut 5' deletion




\*\*\*\*

\*\* \*\*\*\*

\*\*\*\*








a.

e.

30-







% CD69<sup>+</sup> Cells of Total CD4<sup>+</sup> T Cells Untreated  $\alpha$ CD3/ $\alpha$ CD28 Bryostatin RMD AZD5582 🕨 R+B P+B R+A P+A 60 100 20 40 80 0





Figure 4

